Courts should be more strict in trademark violation cases of pharma products: Delhi High Court

The Delhi High Court emphasized the need for stricter measures in trademark violation cases involving pharmaceutical products. The court issued an interim injunction against Sanshiv Health Tech Private Limited, restraining them from marketing ‘Calika-P,’ which was found to be deceptively similar to Mankind Pharma’s ‘Caldikind’ and ‘Caldikind-P.’ The court highlighted the potential for public confusion and the importance of protecting the goodwill and reputation of established pharmaceutical brands.